Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal fosfomycin + metronidazole + molgramostim versus intravenous conventional antibiotics for perforated appendicitis
2017-004753-16Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Nov 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of fosfomycin, metronidazole and sargramostim in perforated appendicitis and acute appendicitis (2 arms), sponsored by Herlev Hospital. Primary endpoint: Total length of hospital stay. Started Nov 2017; status: completed.
02
Drugs
fosfomycinmetronidazolesargramostim
03
Conditions
perforated appendicitisacute appendicitis
Beyond the preview
Go deeper on 2017-004753-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004753-16.